A Phase IB Randomized, Placebo-Controlled Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOE) in Patients With Sickle Cell Disease (SCD)
Latest Information Update: 23 Jul 2024
At a glance
- Drugs Crovalimab (Primary)
- Indications Sickle cell anaemia; Vaso-occlusive crisis
- Focus Adverse reactions
- Acronyms CROSSWALK-a
- Sponsors Roche
- 12 Dec 2023 Trial design presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 24 Aug 2022 Planned End Date changed from 14 Sep 2023 to 14 Jul 2025.
- 24 Aug 2022 Planned primary completion date changed from 14 Sep 2023 to 14 Jan 2025.